First-in-class Protein Degrader Approved for ESR1-mutated Breast Cancer
Vepdegestrant is the first PROTAC approved for any cancer indication. The U.S. Food and Drug Administration (FDA) approved vepdegestrant...
Progress Against Cancer
Vepdegestrant is the first PROTAC approved for any cancer indication. The U.S. Food and Drug Administration (FDA) approved vepdegestrant...
Relacorilant was approved for previously treated ovarian, fallopian tube, and peritoneal cancers. The U.S. Food and Drug Administration (FDA)...
Simultaneously, previous accelerated approvals for nivolumab in relapsed/refractory advanced classical Hodgkin lymphoma were converted to full approvals. The U.S....
The FDA has approved teclistamab with daratumumab hyaluronidase-fihj for certain patients with pretreated multiple myeloma. The U.S. Food and...
Zongertinib was granted accelerated approval as a first-line treatment for adults with advanced non-squamous non-small cell lung cancer with...
The FDA has converted the accelerated approval of encorafenib and cetuximab plus chemotherapy to full approval for first-line treatment...
The second-generation BTK inhibitor acalabrutinib was approved for use with venetoclax. The U.S. Food and Drug Administration (FDA) approved...
The FDA has approved the portable device Optune Pax for non-invasive at-home treatment of locally advanced pancreatic cancer. The...
Pembrolizumab plus paclitaxel, with or without bevacizumab, was approved for PD-L1-positive ovarian, fallopian tube, and peritoneal cancers. The U.S....
The FDA has approved daratumumab and hyaluronidase-fihj in combination with other therapies as first-line treatment for certain patients with...